Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Shire plc | dp47854_8k.htm |
Exhibit 99.1
|
Press Release
|
 |
|
www.shire.com
|
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE
OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO
DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT
LAWS OF SUCH JURISDICTION.
|
For immediate release
|
11 July 2014
|
Shire plc
Statement re: Media Speculation
Shire plc (“Shire” or the “Company”) (LSE: SHP, NASDAQ: SHPG) notes the Bloomberg article this afternoon. Shire confirms it has held a meeting with representatives of AbbVie.
This statement is being made by Shire without the prior agreement or approval of AbbVie.
A further update will be made when appropriate. Shareholders are strongly advised to take no action in relation to AbbVie’s proposal. There can be no certainty that any firm offer will be made nor as to the terms on which any firm offer might be made.
CONTACTS
|
Shire
|
||
|
Stephanie Fagan
|
+1 201 572 9581
|
|
|
FTI Consulting (Media Adviser to the Company)
|
||
|
Andrew Lorenz (London)
|
+44 77 7564 1807
|
|
|
Ben Atwell (London)
|
+44 20 3727 1000
|
|
|
David B. Roady (New York)
|
+1 212 850 5600
|
|
|
Robert Stanislaro (New York)
|
+1 212 850 5600
|
A copy of this announcement will be available at www.shire.com. The content of the website referred to in this announcement is not incorporated into and does not form part of this announcement.
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We focus on providing treatments in Neuroscience, Rare Diseases, Gastrointestinal, and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmology.
www.shire.com
2